Literature DB >> 31587797

Aspirin sensitivity: Lessons in the regulation (and dysregulation) of mast cell function.

Joshua A Boyce1.   

Abstract

The idiosyncratic activation of mast cells (MCs) in response to administration of nonselective COX inhibitors is a cardinal feature of aspirin-exacerbated respiratory disease (AERD). Older studies using MC-stabilizing drugs support a critical role for MCs and their products in driving the severe eosinophilic inflammation and respiratory dysfunction that is typical of AERD. Because patients with AERD react to all nonselective COX inhibitors regardless of their chemical structure, the mechanism of MC activation is not caused by classical, antigen-induced cross-linking of IgE receptors. Recent studies in both human subjects and animal models have revealed a complex and multifactorial process culminating in dysregulation of MC function and an aberrant dependency on COX-1-derived prostaglandin E2 to maintain a tenuous homeostasis. This article reviews the factors most likely to contribute to MC dysregulation in patients with AERD and the potential diagnostic and therapeutic implications.
Copyright © 2019 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Aspirin; asthma; leukotrienes; mast cells; prostaglandins

Mesh:

Year:  2019        PMID: 31587797      PMCID: PMC7735393          DOI: 10.1016/j.jaci.2019.08.022

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  61 in total

1.  Attenuation of aspirin-induced bronchoconstriction by sodium cromoglycate and nedocromil sodium.

Authors:  M Robuschi; G Gambaro; P Sestini; M G Pieroni; R M Refini; A Vaghi; S Bianco
Journal:  Am J Respir Crit Care Med       Date:  1997-04       Impact factor: 21.405

2.  Inflammatory cell populations in bronchial biopsies from aspirin-sensitive asthmatic subjects.

Authors:  S M Nasser; R Pfister; P E Christie; A R Sousa; J Barker; M Schmitz-Schumann; T H Lee
Journal:  Am J Respir Crit Care Med       Date:  1996-01       Impact factor: 21.405

3.  Preferential generation of prostaglandin D2 by rat and human mast cells.

Authors:  R A Lewis; S T Holgate; L J Roberts; J A Oates; K F Austen
Journal:  Kroc Found Ser       Date:  1981

4.  Long-term treatment with aspirin desensitization in asthmatic patients with aspirin-exacerbated respiratory disease.

Authors:  M Pilar Berges-Gimeno; Ronald A Simon; Donald D Stevenson
Journal:  J Allergy Clin Immunol       Date:  2003-01       Impact factor: 10.793

5.  Thymic stromal lymphopoietin activity is increased in nasal polyps of patients with chronic rhinosinusitis.

Authors:  Deepti R Nagarkar; Julie A Poposki; Bruce K Tan; Michael R Comeau; Anju T Peters; Kathryn E Hulse; Lydia A Suh; James Norton; Kathleen E Harris; Leslie C Grammer; Rakesh K Chandra; David B Conley; Robert C Kern; Robert P Schleimer; Atsushi Kato
Journal:  J Allergy Clin Immunol       Date:  2013-05-17       Impact factor: 10.793

6.  Impaired E Prostanoid2 Expression and Resistance to Prostaglandin E2 in Nasal Polyp Fibroblasts from Subjects with Aspirin-Exacerbated Respiratory Disease.

Authors:  Katherine N Cahill; Benjamin A Raby; Xiaobo Zhou; Feng Guo; Derek Thibault; Andreas Baccarelli; Hyang-Min Byun; Neil Bhattacharyya; John W Steinke; Joshua A Boyce; Tanya M Laidlaw
Journal:  Am J Respir Cell Mol Biol       Date:  2016-01       Impact factor: 6.914

7.  Prostaglandin D₂: a dominant mediator of aspirin-exacerbated respiratory disease.

Authors:  Katherine N Cahill; Jillian C Bensko; Joshua A Boyce; Tanya M Laidlaw
Journal:  J Allergy Clin Immunol       Date:  2014-09-11       Impact factor: 10.793

8.  Inhaled PGE2 prevents aspirin-induced bronchoconstriction and urinary LTE4 excretion in aspirin-sensitive asthma.

Authors:  P Sestini; L Armetti; G Gambaro; M G Pieroni; R M Refini; A Sala; A Vaghi; G C Folco; S Bianco; M Robuschi
Journal:  Am J Respir Crit Care Med       Date:  1996-02       Impact factor: 21.405

9.  Plasma tryptase elevation during aspirin-induced reactions in aspirin-exacerbated respiratory disease.

Authors:  Katherine N Cahill; Katherine Murphy; Joseph Singer; Elliot Israel; Joshua A Boyce; Tanya M Laidlaw
Journal:  J Allergy Clin Immunol       Date:  2018-10-16       Impact factor: 10.793

10.  The cysteinyl leukotriene 3 receptor regulates expansion of IL-25-producing airway brush cells leading to type 2 inflammation.

Authors:  Lora G Bankova; Daniel F Dwyer; Eri Yoshimoto; Saltanat Ualiyeva; John W McGinty; Hannah Raff; Jakob von Moltke; Yoshihide Kanaoka; K Frank Austen; Nora A Barrett
Journal:  Sci Immunol       Date:  2018-10-05
View more
  5 in total

1.  Mediator production and severity of aspirin-induced respiratory reactions: Impact of sampling site and body mass index.

Authors:  Katherine N Cahill; Pingsheng Wu; Ginger L Milne; Taneem Amin; Joseph Singer; Katherine Murphy; Erin Lewis; Deborah Gapko; Joshua A Boyce; Katherine M Buchheit; Tanya M Laidlaw
Journal:  J Allergy Clin Immunol       Date:  2022-01-11       Impact factor: 14.290

2.  Biomarkers for predicting response to aspirin therapy in aspirin-exacerbated respiratory disease.

Authors:  Katarzyna E Tyrak; Kinga Pajdzik; Bogdan Jakieła; Izabela Kupryś-Lipińska; Adam Ćmiel; Radosław Kacorzyk; Gabriela Trąd; Piotr Kuna; Marek Sanak; Lucyna Mastalerz
Journal:  Clin Exp Allergy       Date:  2021-05-11       Impact factor: 5.401

Review 3.  Systematic review of outcomes for endoscopic sinus surgery and subsequent aspirin desensitization in aspirin-exacerbated respiratory disease.

Authors:  Lindsey Ryan; Daniel Segarra; Mark Tabor; Arjun Parasher
Journal:  World J Otorhinolaryngol Head Neck Surg       Date:  2020-11-16

4.  Does IgE Have a Role in Aspirin-exacerbated Respiratory Disease?

Authors:  William W Busse
Journal:  Am J Respir Crit Care Med       Date:  2020-06-15       Impact factor: 21.405

5.  Omalizumab for Aspirin Hypersensitivity and Leukotriene Overproduction in Aspirin-exacerbated Respiratory Disease. A Randomized Controlled Trial.

Authors:  Hiroaki Hayashi; Yuma Fukutomi; Chihiro Mitsui; Keiichi Kajiwara; Kentaro Watai; Yosuke Kamide; Yuto Nakamura; Yuto Hamada; Yasuhiro Tomita; Kiyoshi Sekiya; Takahiro Tsuburai; Kenji Izuhara; Keiko Wakahara; Naozumi Hashimoto; Yoshinori Hasegawa; Masami Taniguchi
Journal:  Am J Respir Crit Care Med       Date:  2020-06-15       Impact factor: 21.405

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.